TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced its participation in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:00 a.m. ET. The event will focus on T-cell receptor (TCR) engineered therapies aimed at treating cancer. Interested parties can access a live webcast via the company’s website, with an archived replay available for 30 days post-event. TScan specializes in innovative TCR-T therapies, including candidates TSC-100 and TSC-101 targeting hematologic malignancies.

WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the LifeSci 2^nd Annual Genetic Medicines Symposium on Tuesday, June 28, 2022, at 9:00 a.m. ET.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at www.ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts:

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com 

FAQ

What is the date and time of TScan Therapeutics' fireside chat?

The fireside chat is scheduled for June 28, 2022, at 9:00 a.m. ET.

Where can I watch the TScan Therapeutics fireside chat?

The fireside chat can be accessed through the 'Events and Presentations' section of TScan's website.

What is the focus of TScan Therapeutics at the symposium?

TScan will discuss its T-cell receptor (TCR) engineered T cell therapies for cancer treatment.

How long will the archived replay of the TScan fireside chat be available?

The archived replay will be available for 30 days following the event.

What types of therapies does TScan Therapeutics develop?

TScan develops T cell receptor (TCR) engineered T cell therapies, including TSC-100 and TSC-101 for hematologic malignancies.